The biotech is exploring opportunities for a reverse merger or other business combinations. CFO and now interim CEO Anup ...

Confluent (NASDAQ:CFLT – Get Free Report)‘s stock had its “outperform” rating reissued by analysts at William Blair in a ...

Fintel reports that on March 17, 2025, William Blair upgraded their outlook for DocuSign (NasdaqGS:DOCU) from Market Perform ...

Fintel reports that on March 18, 2025, William Blair downgraded their outlook for Incyte (NasdaqGS:INCY) from Outperform to Market Perform. Analyst Price Forecast Suggests 28.39% Upside As of March 4, ...

Analysts at William Blair lowered their Q1 2025 earnings estimates for Legend Biotech in a research report issued to clients ...

JPMorgan Chase & Co. has hired William Kallop from William Blair & Co. for its mergers and acquisitions group focused on ...

The firm upgraded Palantir from Underperform to Market Perform after a sharp stock decline but did not assign a price target.

William Blair analyst Louie DiPalma maintained a Hold rating on Science Applications (SAIC – Research Report) today. The company’s shares ...

William Blair downgraded Udemy (UDMY) to Market Perform from Outperform after the company announced the appointment of Hugo Sarrazin as president and CEO, effective immediately, to succeed Greg Brown.

The embedded finance company, which posted a loss last year, hired Citi to explore its strategic options and named an interim ...

Investing.com -- William Blair analysts issued a cautionary note on Palantir Technologies (NASDAQ:PLTR), highlighting potential downside risk for the stock despite continued commercial momentum.

The note emphasized that Palantir shares declined 10% following a 4% selloff in the Nasdaq, and if the broader market ...